Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.59 |
| ▸ | NTSR1 | P30989 | 7/20 | 0.54 |
| ▸ | NTSR2 | O95665 | 6/20 | 0.54 |
| ▸ | SORT1 | Q99523 | 5/20 | 0.54 |
| ▸ | CALCRL | Q16602 | 2/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30327395 | 0.97 | SLC6A2 (0.55) | SLC6A2NTSR1NTSR2SORT1CALCRL | |
| SCHEMBL30335654 | 0.94 | NTSR1 (0.55) | SLC6A2NTSR1NTSR2SORT1OPRM1 | |
| SCHEMBL32670390 | 0.91 | SLC6A2 (0.59) | SLC6A2NTSR1NTSR2SORT1CALCRL | |
| SCHEMBL30327364 | 0.91 | OPRM1 (0.54) | SLC6A2NTSR1NTSR2SORT1OPRM1 | |
| SCHEMBL32670304 | 0.91 | SLC6A2 (0.54) | SLC6A2NTSR1NTSR2SORT1OPRM1 | |
| SCHEMBL29463750 | 0.90 | CALCR (0.57) | NTSR1NTSR2SORT1OPRM1OPRD1 | |
| SCHEMBL29903290 | 0.89 | CALCRL (0.57) | SLC6A2CALCRL | |
| SCHEMBL31415956 | 0.87 | SLC6A2 (0.61) | SLC6A2NTSR1NTSR2SORT1CALCRL | |
| SCHEMBL30327416 | 0.87 | NPY2R (0.58) | — | |
| SCHEMBL30751612 | 0.86 | CALCR (0.54) | SLC6A2NTSR1NTSR2SORT1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034197-A1 | Peptides and Fragments for Treating Diabetes and Associated Metabolic Diseases | BETAVIVE LTD. (IL) | 2026-02-05 | — | — | US | disclosed |
| US-12447198-B2 | Peptides and fragments for treating diabetes and associated metabolic diseases | BETAVIVE LTD. (IL) | 2025-10-21 | — | — | US | disclosed |
| US-20230120635-A1 | Peptides and Fragments for Treating Diabetes and Associated Metabolic Diseases | BETAVIVE LTD. (IL) | 2023-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230120635-A1 | Peptides and Fragments for Treating Diabetes and Associated Metabolic Diseases | IAPP, IGFBP2, IGFBP1 | SLC6A2 3853/4885NTSR1 178/4885NTSR2 88/4885 |
| US-12447198-B2 | Peptides and fragments for treating diabetes and associated metabolic diseases | IAPP, IGFBP2, IGFBP1 | SLC6A2 3853/4885NTSR1 178/4885NTSR2 88/4885 |
| US-20260034197-A1 | Peptides and Fragments for Treating Diabetes and Associated Metabolic Diseases | IAPP, GLP1R, IGF1R | SLC6A2 1712/4885NTSR1 271/4885NTSR2 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.